The world’s first intranasal Covid-19 vaccine, developed by Hyderabad-based pharmaceutical firm Bharat Biotech, has been approved for restricted emergency use as heterologous booster doses in adults. The vaccine, called iNCOVACC, can now be administered in people aged 18 years and above as primary doses, as well as heterologous booster doses. The latter means that a person can receive a different vaccine from the one that was used for the primary dose series.
The vaccine has received approval for restricted use in emergency situations from the Central Drugs Standard Control Organisation (CDSCO), Bharat Biotech announced on November 28.
iNCOVACC, World’s first intranasal vaccine to receive both primary series and Heterologous booster approval. #bharatbiotech #incovacc #intranasalvaccine #vaccine #COVID19 #VaccinesWork #VaccineDevelopment #Booster #COVID #pandemic #firstintranasalvaccine pic.twitter.com/jyTebvwiT6
— BharatBiotech (@BharatBiotech) November 28, 2022
(This is BREAKING News. Please refresh the page for more updates)
Check out below Health Tools-
Calculate Your Body Mass Index ( BMI )
